SparingVision is a company.
SparingVision has raised $128.0M across 2 funding rounds.
Key people at SparingVision.
SparingVision has raised $128.0M in total across 2 funding rounds.
Key people at SparingVision.
SparingVision has raised $128.0M in total across 2 funding rounds.
SparingVision's investors include 4BIO Capital.
SparingVision is a clinical-stage genomic medicines company developing vision-saving gene therapies for retinal diseases causing blindness, such as retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).[1][2][4] It serves patients with inherited retinal diseases (IRDs) and geographic atrophy, addressing the unmet need for lasting treatments beyond single-gene corrections by using mutation-agnostic approaches like delivering rod-derived cone viability factor (RdCVF) via SPVN06 to protect cone photoreceptors and preserve central vision.[1][4][5] The company has grown from 4 employees in 2016 to nearly 40, raised €60 million from investors including 4BIO Capital, Bpifrance, and UPMC Enterprises, and advanced to Phase I/II trials for SPVN06 (PRODYGY trial), earning recognition as a 2023 Fierce 15 company for its innovative pipeline.[1][2][3]
SparingVision was founded in 2016 by Prof. José-Alain Sahel, an ophthalmology expert and director of the UPMC Vision Institute, and the late Dr. Thierry Léveillard, a French researcher, to translate over 20 years of pioneering ophthalmic research from the Paris Vision Institute into treatments for blindness.[1][2][5] The idea emerged from their discovery of RdCVF, a protein secreted by rod photoreceptors essential for cone survival; in RP, rod death deprives cones of RdCVF, leading to central vision loss, prompting a "genotype-independent" gene therapy strategy applicable to all RP patients regardless of mutation.[1][5] Early traction included rapid growth to clinical phases, strategic acquisition of GAMUT Therapeutics to add SPVN20 (a GIRK channel therapy for dormant cones), and investor backing that fueled pipeline expansion.[1][2]
SparingVision rides the wave of genomic medicine advancements in ophthalmology, shifting from mutation-specific therapies to broader, gene-independent platforms amid rising demand for IRD/AMD treatments affecting millions worldwide without cures.[1][3][5] Timing aligns with maturing AAV vectors, CRISPR progress, and clinical successes in gene therapy, amplified by market forces like aging populations driving AMD prevalence and investor focus on high-unmet-need areas.[2][3] It influences the ecosystem by pioneering combo therapies (e.g., SPVN06+SPVN20), fostering collaborations (Intellia), and setting benchmarks for biotech innovation, as evidenced by Fierce Biotech's endorsement amid intense competition.[3][5]
SparingVision is poised to disrupt ocular therapeutics with Phase I/II data from PRODYGY expected to validate SPVN06's broad RP applicability, alongside SPVN20 advancement and CRISPR partnerships potentially yielding combo regimens for advanced disease.[2][3][5] Trends like AI-accelerated trial design, expanded AAV payloads, and regulatory nods for gene therapies will accelerate its path to approvals, evolving its influence from pipeline innovator to ecosystem leader in vision restoration.[1][4] This positions SparingVision to deliver on its mission of lasting blindness treatments, transforming patient outcomes where none existed.
SparingVision has raised $128.0M across 2 funding rounds. Most recently, it raised $75.0M Series B in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $75.0M Series B | 4BIO Capital | |
| Oct 1, 2020 | $53.0M Series A | 4BIO Capital |
